Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Indication-Based Pricing Could Be Windfall For Interleukin Inhibitors

Executive Summary

Express Scripts' plan to reimburse at levels according to value of specific indications in inflammatory diseases will create more space for new entrants with proven value.

Advertisement

Related Content

Can New Drugs Meet Lilly’s Revenue Goals If Solanezumab Fails?
3Q Pharma Results Preview: Novartis, Merck, Lilly, Bayer, GSK, Bristol, Amgen, Sanofi
FDA Biosimilar Policy Continues To Evolve With Approval Of Sandoz Erelzi
Pfizer/Celltrion Prep For October Inflectra Launch
Does Novartis Need A Big Immuno-Oncology Deal? Jimenez Says No
New Data Bolsters Cosentyx In AS & PsA; Humira Head-To-Head Planned
Payer Briefs: Express Scripts Pricing Pilot; HHS Risk Adjustment; Value Frameworks
FDA OK's Lilly's Taltz; Rival To Novartis' Cosentyx
CVS Indication-Based Pricing For Cancer Drugs May Roll Out Later In 2016
New Interleukin Inhibitors May Give Stelara A Run For The Psoriasis Money

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register